Contact Information
NERA Economic Consulting
1255 23rd Street, NW
Suite 600
Washington, DC 20037
tel: +1 202 466 9295
fax: +1 202 466 3605
Education

PhD and MA in economics, University of Iowa


MA in mathematics, University of Minnesota


BA in mathematics, College of St. Thomas
Dr. Richard Rozek
Senior Vice President, Washington, DC

Dr. Rozek works on projects involving intellectual property, antitrust, and transfer pricing across a variety of industries.

Assignments in which he has participated include:

  		•

    Analyses and testimony for plaintiffs or defendants on economic issues in antitrust, contract dispute, false advertising, patent/trademark/copyright/trade secret, personal injury, and libel matters;

  • Transfer pricing studies following US, Organisation for Economic Co-Operation and Development (OECD), or specific foreign tax rules for tangible and intangible property in transportation, consumer product, medical devices/instruments, pharmaceutical, and professional service industries;

  • Public policy studies on pharmaceutical industry issues such as improving intellectual property protection, limiting parallel trade, and assessing the impact of health care reform initiatives on innovation and prices;

  • Design of auctions for power generation and professional sports markets;

  • Testimony on deficiencies in state hospital rate regulation schemes; and

  • Estimates of the data compensation payable under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).


    Prior to joining NERA, Dr. Rozek held senior positions in the Bureau of Economics at the US Federal Trade Commission, where he served as Deputy Assistant Director for Antitrust, and at the Pharmaceutical Manufacturers Association (now called Pharmaceutical Research and Manufacturers of America). He also was an Assistant Professor of Economics at the University of Pittsburgh.

    Dr. Rozek has written over 45 articles for professional journals such as the American Economist, Contemporary Policy Issues, Electricity Journal, Energy Journal, Economics Letters, Journal of Economic Integration, Journal of Economics, Journal of Research in Pharmaceutical Economics, Journal of World Intellectual Property, Mathematical Modelling, Research Policy, and Tax Notes International. He is frequently invited to speak on developments in intellectual property protection for pharmaceuticals.

    Selected Publications
    Key Factors in Attracting Internationally Mobile Investments by the Research-Based Pharmaceutical Industry   21 September 2007.

    Patent Wars and Authorised Generics in the USA: Assessing the Issues   1 May 2007.

    The Intellectual Property Debate: Perspectives from Law, Economics and Political Economy   1 August 2006.

    A Market-Based Approach for Tangible Property Transfer Pricing   16 March 2005.

    Economic Issues Raised in the FDA’s Proposed Rule on Removing the Essential-Use Designation for Albuterol MDIs   13 August 2004.

    Using In-country Comparables to Measure the Returns Due Pharmaceutical Marketing and Distribution Affiliates   1 December 2003.

    Investment Incentives Created by the Montreal Protocol and FDA Policy on Albuterol   20 November 2003.

    The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone Depleting Substance   9 September 2003.

    Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Policy   1 July 2001.

    The WTO Dispute Settlement Mechanism: TRIPS Rulings and the Developing Countries: Prospects After Seattle   1 March 2001.

    The Effects of Compulsory Licensing on Innovation and Access to Health Care   1 November 2000.

    Valuing Intellectual Property Assets for Licensing   1 June 2000.

    Transfer Prices for the Intangible Property Embodied in Products with Extraordinary Profit Potentials   1 October 1999.

    The Costs to the US Health Care System of Extending Marketing Exclusivity for Taxol   1 September 1999.

    The TRIPS Agreement and Access to Health Care   1 September 1999.

    Regulatory Influences on the Decision to Introduce Pharmaceutical Products in Japan   1 September 1998.

    The Effects of Patent Protection on the Prices of Pharmaceutical Products - Is IP Protection Raising the Drug Bill in Developing Countries?   1 March 1998.

    Applying the Best Method Rule When Reliable Internal Comparable Intangibles Exist   8 April 1996.

    Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation   1 September 1992.

    Discounted Cash Flow Analysis in Patent Infringement Litigation   1 September 1991.

    Benefits and Costs of Intellectual Property Protection in Developing Countries   1 October 1990.

    Client Experience
    Alza Corporation and McNeil-PPC, Inc. vs. Andrx Pharmaceuticals, LLC and Andrx Corporation
    Economic Advice in Litigation

    LifeNet, Inc. vs. Musculoskeletal Transplant Foundation, Inc.
    Economic Advice in Litigation

    Janssen Pharmaceutica N.V., et al. v. Eon Labs Manufacturing, Inc.
    Economic Advice in Litigation

    Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc.
    Economic Advice in Litigation

    NERA Dialogue Sessions
    FICPI World Congress

    Washington, DC

    7 June 2009
    Federal Trade Commission/Department of Justice Hearings on Single-Firm Conduct

    Washington, DC

    6 December 2006
    Mid-Atlantic BIO/MED Venture and Investment Forum

    Baltimore, MD

    3 December 2003
    Calculating & Proving Patent Damages

    McLean, VA

    16 June 2003
     
    ©1996-2010 National Economic Research Associates, Inc.
    All Rights Reserved
    Privacy policy | Site map | Experts | Contact us